Classes
DEA Class; Rx
Common Brand Names; Crixivan
- Antiretroviral Agents;
- HIV, Protease Inhibitors
Description
Protease inhibitor (PI)
Indicated to treat HIV infection in combination with other antiretrovirals
Potential for nephrolithiasis
Indications
Indicated for the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents.
Contraindications
Hypersensitivity
Drugs that are contraindicated with indinavir include alpha1-adrenoreptor agonists (eg, alfuzosin), antiarrhythmics (amiodarone, bepridil, flecainide, propafenone, quinidine), rifampin, voriconazole, ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine), cisapride, St. John’s wort, lovastatin, simvastatin, lurasidone, pimozide, sildenafil (when used for pulmonary artery hypertension), midazolam, and triazolam
Adverse Effects
- Nephrolithiasis/urolithiasis (29%, peds)
- Hyperbilirubinemia (14%)
- Nausea (12%)
- Pain (17%)
- Nephrolithiasis/urolithiasis (12%, adults)
- Abdominal pain (9%)
- Thrombocytopenia (1%)
- Back pain (8%)
- Dysuria (2%)
- Headache (6%)
- Fever (2%)
- Dizziness (3%)
- Diarrhea/vomiting (4-5%)
- Weakness (4%)
- Malaise (2%)
- Insomnia (3%)
- Fatigue (2%)
- Taste perversion (3%)
- Flank pain (3%)
- Pruritus (4%)
- Neutropenia (2%)
- Cough (2%)
Warnings
Proper hydration required (1.5 L liquids/day) to counter risk of nephrolithiasis/urolithiasis (much higher in children)
Risks of fat redistribution, hemolytic anemia, hyperglycemia, hyperbilirubinemia, immune reconstitution syndrome if used in combination w/ other antiretroviral drugs
Separate from didanosine by 1 hr
Monitor: LFTs q6-12week
Pregnancy and Lactation
There are insufficient prospective pregnancy data from Antiretroviral Pregnancy Registry (APR) to adequately assess risk of adverse developmental outcomes
There is no information available on presence of amprenavir in human milk, the effects of the drug on breastfed infant, or effects of drug on milk production
Maximum Dosage
NOTE: The following maximum dosage limits apply for typical indinavir use; maximum dosage limits may be altered based on certain individual patient circumstances, such as in the case of specific drug interactions.
2400 mg/day PO.
2400 mg/day PO.
Dosage not definitively established; 2400 mg/day PO has been recommended.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
Indinavir sulfate
capsules
- 100mg
- 200mg
- 400mg
